FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Low Number of Drug Recalls in Third Quarter: Stericycle
11/13/2019
 
 
TXT Trump Changing Drug Price Plan
11/13/2019
 
 
TXT FDA Warns Dollar Tree on Unsafe OTC Drugs
11/14/2019
 
 
TXT Generics See Mixed Results on Obtaining Samples: GAO
11/15/2019
 
 
TXT CGMP Deviations Found in Mylan Unit 8
11/12/2019
 
 
TXT FDA Clears ‘Safer’ Pentax Duodenoscope
11/15/2019
 
 
TXT ICH Q12 Guidance Extends Quality by Design: Analysis
11/14/2019
 
 
TXT Pull LASIK Off Market: Waxler
11/14/2019
 
 
TXT Revise Anti-Infective Drug Development Outcomes: Study
11/13/2019
 
 
TXT FDA Making Less Use of Advisory Committees: Analysis
11/13/2019
 
 
TXT Cadila Healthcare CGMP Violations
11/12/2019
 
 
TXT Product Approval Summaries
11/17/2019
 
 
TXT Since Our Last Issue ...
11/17/2019
 
 
TXT Latest Federal Register Notices
11/17/2019
 
 
TXT Guidance on Smallpox Drug Development
11/15/2019
 
 
TXT Panel Backs Expanded Vascepa Use
11/15/2019
 
 
TXT FDA Funds Quality Management Research Project
11/14/2019
 
 
TXT Panel Nixes Lilly/Boehringer Diabetes Drug
11/14/2019
 
 
TXT Isorx FDA-483 Released
11/13/2019
 
 
TXT Export Certificate Review Process Guidance
11/13/2019
 
 
TXT Supreme Court to Consider Disgorgement Legality
11/13/2019
 
 
TXT Panel Urges Risk-based Sterility Assurance for Devices
11/12/2019
 
 
TXT 3 IMDRF Clinical Documents Published
11/12/2019
 
 
TXT Latest FDA Warning Letters
11/12/2019
 
 
TXT Potential Dietary Supplement Statutory Changes
11/12/2019
 
 
TXT Firm Sues FDA to Reverse Clinical Hold
11/11/2019
 
 
TXT FDA Rejects Lipocine NDA for Testosterone Drug
11/11/2019
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving